Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2018, Article ID 8671832, 20 pages
https://doi.org/10.1155/2018/8671832
Review Article

Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors

1James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA
2Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, IN, USA
3Department of Oncology, Oslo University Hospital, Radium Hospital, Oslo, Norway

Correspondence should be addressed to Chunkit Fung; ude.retsehcor.cmru@gnuf_tiknuhc

Received 29 August 2017; Accepted 6 December 2017; Published 18 February 2018

Academic Editor: Aditya Bagrodia

Copyright © 2018 Chunkit Fung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer Statistics, 2017,” CA: A Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7–30, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. L. H. Einhorn and J. Donohue, “Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer,” Annals of Internal Medicine, vol. 87, no. 3, pp. 293–298, 1977. View at Publisher · View at Google Scholar
  3. N. Hanna and L. H. Einhorn, “Testicular cancer: a reflection on 50 years of discovery,” Journal of Clinical Oncology, vol. 32, no. 28, pp. 3085–3092, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Verdecchia, S. Francisci, H. Brenner et al., “Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data,” Lancet Oncology, vol. 8, no. 9, pp. 784–796, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. L. H. Einhorn, “Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture,” Cancer Research, vol. 41, no. 1, pp. 3275–3280, 1981. View at Google Scholar
  6. L. B. Travis, A. K. Ng, J. M. Allan et al., “Second malignant neoplasms and cardiovascular disease following radiotherapy,” Journal of the National Cancer Institute, vol. 104, no. 5, pp. 357–370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. H. S. Haugnes, G. J. Bosl, H. Boer et al., “Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up,” Journal of Clinical Oncology, vol. 30, no. 30, pp. 3752–3763, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. N. M. Aziz, “Cancer survivorship research: state of knowledge, challenges and opportunities,” Acta Oncologica, vol. 46, no. 4, pp. 417–432, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. D. R. Feldman, W. L. Schaffer, and R. M. Steingart, “Late cardiovascular toxicity following chemotherapy for germ cell tumors,” Journal of the National Comprehensive Cancer Network, vol. 10, no. 4, pp. 537–544, 2012. View at Publisher · View at Google Scholar
  10. J. F. Christensen, M. Bandak, A. Campbell, L. W. Jones, and P. Højman, “Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship,” Acta Oncologica, vol. 54, no. 5, pp. 592–599, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Y. Dirix, M. Libura, J. Libura, P. B. Vermeulen, E. A De Bruijn, and A. T. Van Oosterom, “In vitro toxicity studies with mitomycins and bleomycin on endothelial cells,” Anticancer Drugs, vol. 8, no. 9, pp. 859–868, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Shi, S. Inoue, R. Shinozaki, K. Fukue, and T. Kougo, “Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro,” Japanese Journal of Cancer Research, vol. 89, no. 7, pp. 757–767, 1998. View at Publisher · View at Google Scholar
  13. K. P. Dieckmann, W. J. Struss, and U. Budde, “Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour,” Anticancer Research, vol. 31, no. 12, pp. 4501–4505, 2011. View at Google Scholar
  14. J. Nuver, A. J. Smit, D. T. Sleijfer et al., “Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer,” European Journal of Cancer, vol. 40, no. 5, pp. 701–706, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Nuver, A. J. Smit, J. van der Meer et al., “Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9130–9137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. T. Meinardi, J. A. Gietema, W. T. van der Graaf et al., “Cardiovascular morbidity in long-term survivors of metastatic testicular cancer,” Journal of Clinical Oncology, vol. 18, no. 8, pp. 1725–1732, 2000. View at Publisher · View at Google Scholar
  17. H. C. Gerstein, J. F. Mann, Q. Yi et al., “Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals,” Journal of the American Medical Association, vol. 286, no. 4, pp. 421–426, 2001. View at Publisher · View at Google Scholar
  18. D. H. O'Leary, J. F. Polak, R. A. Kronmal et al., “Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group,” New England Journal of Medicine, vol. 340, no. 1, pp. 14–22, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. L. D. van Schinkel, P. M. Willemse, R. W. van der Meer et al., “Chemotherapy for testicular cancer induces acute alterations in diastolic heart function,” British Journal of Cancer, vol. 109, no. 4, pp. 891–896, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. D. J. Brenner and E. J. Hall, “Computed tomography–an increasing source of radiation exposure,” New England Journal of Medicine, vol. 357, no. 22, pp. 2277–2284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. R. L. Schilsky and T. Anderson, “Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin,” Annals of Internal Medicine, vol. 90, no. 6, pp. 929–931, 1979. View at Publisher · View at Google Scholar
  22. P. D. Turlapaty and B. M. Altura, “Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease,” Science, vol. 208, no. 4440, pp. 198–200, 1980. View at Publisher · View at Google Scholar
  23. N. J. Vogelzang, J. L. Torkelson, and B. J. Kennedy, “Hypomagnesemia, renal dysfunction, and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin,” Cancer, vol. 56, no. 12, pp. 2765–2770, 1985. View at Publisher · View at Google Scholar
  24. G. I. Togna, A. R. Togna, M. Franconi, and L. Caprino, “Cisplatin triggers platelet activation,” Thrombosis Research, vol. 99, no. 5, pp. 503–509, 2000. View at Publisher · View at Google Scholar
  25. D. Lechner, M. Kollars, A. Gleiss, P. A. Kyrle, and A. Weltermann, “Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity,” Journal of Thrombosis and Haemostasis, vol. 5, no. 12, pp. 2445–2452, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Bissett, L. Kunkeler, L. Zwanenburg et al., “Long-term sequelae of treatment for testicular germ cell tumours,” British Journal of Cancer, vol. 62, no. 4, pp. 655–659, 1990. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Bokemeyer and H. J. Schmoll, “Secondary neoplasms following treatment of malignant germ cell tumors,” Journal of Clinical Oncology, vol. 11, no. 9, pp. 1703–1709, 1993. View at Publisher · View at Google Scholar
  28. M. Brydoy, J. Oldenburg, O. Klepp et al., “Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors,” Journal of the National Cancer Institute, vol. 101, no. 24, pp. 1682–1695, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. J. L. Glendenning, Y. Barbachano, A. R. Norman et al., “Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer,” Cancer, vol. 116, no. 10, pp. 2322–2331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Strumberg, S. Brugge, M. W. Korn et al., “Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer,” Annals of Oncology, vol. 13, no. 2, pp. 229–236, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. R. de Wit, G. Stoter, S. B. Kaye et al., “Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group,” Journal of Clinical Oncology, vol. 15, no. 5, pp. 1837–1843, 1997. View at Publisher · View at Google Scholar
  32. C. Bokemeyer, C. C. Berger, M. A. Kuczyk, and H. J. Schmoll, “Evaluation of long-term toxicity after chemotherapy for testicular cancer,” Journal of Clinical Oncology, vol. 14, no. 11, pp. 2923–2932, 1996. View at Publisher · View at Google Scholar
  33. H. S. Haugnes, N. Aass, S. D. Fossa et al., “Components of the metabolic syndrome in long-term survivors of testicular cancer,” Annals of Oncology, vol. 18, no. 2, pp. 241–248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. H. S. Haugnes, T. Wethal, N. Aass et al., “Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study,” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4649–4657, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. R. A. Huddart, A. Norman, M. Shahidi et al., “Cardiovascular disease as a long-term complication of treatment for testicular cancer,” Journal of Clinical Oncology, vol. 21, no. 8, pp. 1513–1523, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Nuver, A. J. Smit, B. H. Wolffenbuttel et al., “The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer,” Journal of Clinical Oncology, vol. 23, no. 16, pp. 3718–3725, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Sagstuen, N. Aass, S. D. Fossa et al., “Blood pressure and body mass index in long-term survivors of testicular cancer,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 4980–4990, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. P. M. Willemse, J. Burggraaf, N. A. Hamdy et al., “Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors,” British Journal of Cancer, vol. 109, no. 1, pp. 60–67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. E. C. de Haas, R. Altena, H. M. Boezen et al., “Early development of the metabolic syndrome after chemotherapy for testicular cancer,” Annals of Oncology, vol. 24, no. 3, pp. 749–755, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Fung, H. D. Sesso, A. M. Williams et al., “Multi-institutional assessment of adverse health outcomes among north American testicular cancer survivors after modern cisplatin-based chemotherapy,” Journal of Clinical Oncology, vol. 35, no. 11, pp. 1211–1222, 2017. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Bogefors, S. Isaksson, J. Bobjer et al., “Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome,” Andrology, vol. 5, no. 4, pp. 711–717, 2017. View at Publisher · View at Google Scholar
  42. A. M. Traish, F. Saad, R. J. Feeley, and A. Guay, “The dark side of testosterone deficiency: III. Cardiovascular disease,” Journal of Andrology, vol. 30, no. 5, pp. 477–494, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. A. M. Traish, F. Saad, and A. Guay, “The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance,” Journal of Andrology, vol. 30, no. 5, pp. 23–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. M. Traish, A. Guay, R. Feeley, and F. Saad, “The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction,” Journal of Andrology, vol. 30, no. 5, pp. 10–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. L. W. Jones, M. J. Haykowsky, J. J. Swartz, P. S. Douglas, and J. R. Mackey, “Early breast cancer therapy and cardiovascular injury,” Journal of the American College of Cardiology, vol. 50, no. 15, pp. 1435–1441, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. W. van den Belt-Dusebout, R. de Wit, J. A. Gietema et al., “Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer,” Journal of Clinical Oncology, vol. 25, no. 28, pp. 4370–4378, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. A. W. van den Belt-Dusebout, J. Nuver, R. de Wit et al., “Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 467–475, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. S. D. Fossa, E. Gilbert, G. M. Dores et al., “Noncancer causes of death in survivors of testicular cancer,” Journal of the National Cancer Institute, vol. 99, no. 7, pp. 533–544, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. S. R. Alanee, D. R. Feldman, P. Russo et al., “Long-term mortality in patients with germ cell tumors: effect of primary cancer site on cause of death,” Urologic Oncology, vol. 32, no. 1, pp. 26.e9–26.e15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Fung, S. D. Fossa, M. T. Milano et al., “Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study,” Journal of Clinical Oncology, vol. 33, no. 28, pp. 3105–3115, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart disease and stroke statistics–2014 update: a report from the American Heart Association,” Circulation, vol. 129, no. 3, pp. e28–e292, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. D. C. Goff Jr., D. M. Lloyd-Jones, G. Bennett et al., “2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Circulation, vol. 129, no. 2, pp. S49–S73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. M. E. Wood, V. Vogel, A. Ng, L. Foxhall, P. Goodwin, and L. B. Travis, “Second malignant neoplasms: assessment and strategies for risk reduction,” Journal of Clinical Oncology, vol. 30, no. 30, pp. 3734–3745, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. L. B. Travis, C. S. Rabkin, L. M. Brown et al., “Cancer survivorship–genetic susceptibility and second primary cancers: research strategies and recommendations,” Journal of the National Cancer Institute, vol. 98, no. 1, pp. 15–25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. L. B. Travis, S. D. Fossa, S. J. Schonfeld et al., “Second cancers among 40,576 testicular cancer patients: focus on long-term survivors,” Journal of the National Cancer Institute, vol. 97, no. 18, pp. 1354–1365, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. L. B. Travis, M. Andersson, M. Gospodarowicz et al., “Treatment-associated leukemia following testicular cancer,” Journal of the National Cancer Institute, vol. 92, no. 14, pp. 1165–1171, 2000. View at Publisher · View at Google Scholar
  57. L. B. Travis, R. E. Curtis, H. Storm et al., “Risk of second malignant neoplasms among long-term survivors of testicular cancer,” Journal of the National Cancer Institute, vol. 89, no. 19, pp. 1429–1439, 1997. View at Publisher · View at Google Scholar
  58. M. Hauptmann, S. D. Fossa, M. Stovall et al., “Increased stomach cancer risk following radiotherapy for testicular cancer,” British Journal of Cancer, vol. 112, no. 1, pp. 44–51, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Hauptmann, T. Borge Johannesen, E. S. Gilbert et al., “Increased pancreatic cancer risk following radiotherapy for testicular cancer,” British Journal of Cancer, vol. 115, no. 7, pp. 901–908, 2016. View at Publisher · View at Google Scholar · View at Scopus
  60. A. W. van den Belt-Dusebout, B. M. Aleman, G. Besseling et al., “Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy,” International Journal of Radiation Oncology, Biology, Physics, vol. 75, no. 5, pp. 1420–1429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. J. M. Bachaud, F. Berthier, M. Soulie et al., “Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma,” Radiotherapy and Oncology, vol. 50, no. 2, pp. 191–197, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. N. H. Hanna and L. H. Einhorn, “Testicular cancer–discoveries and updates,” New England Journal of Medicine, vol. 371, no. 21, pp. 2005–2016, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. D. F. Bajorin, M. F. Sarosdy, D. G. Pfister et al., “Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study,” Journal of Clinical Oncology, vol. 11, no. 4, pp. 598–606, 1993. View at Publisher · View at Google Scholar
  64. C. Kollmannsberger, J. Beyer, J. P. Droz et al., “Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3386–3391, 1998. View at Publisher · View at Google Scholar
  65. C. Kollmannsberger, J. T. Hartmann, L. Kanz et al., “Therapy-related malignancies following treatment of germ cell cancer,” International Journal of Cancer, vol. 83, no. 6, pp. 860–863, 1999. View at Publisher · View at Google Scholar
  66. E. H. Wanderas, S. D. Fossa, and S. Tretli, “Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients,” European Journal of Cancer, vol. 33, no. 2, pp. 253–262, 1997. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Fung, S. D. Fossa, M. T. Milano, J. Oldenburg, and L. B. Travis, “Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study,” Journal of Clinical Oncology, vol. 31, no. 30, pp. 3807–3814, 2013. View at Publisher · View at Google Scholar
  68. S. D. Fossa, J. Chen, S. J. Schonfeld et al., “Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men,” Journal of the National Cancer Institute, vol. 97, no. 14, pp. 1056–1066, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. P. B. Rossen, A. F. Pedersen, R. Zachariae, and H. von der Maase, “Health-related quality of life in long-term survivors of testicular cancer,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5993–5999, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. S. D. Williams, R. Birch, L. H. Einhorn, L. Irwin, F. A. Greco, and P. J. Loehrer, “Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide,” New England Journal of Medicine, vol. 316, no. 23, pp. 1435–1440, 1987. View at Publisher · View at Google Scholar
  71. M. Sprauten, T. H. Darrah, D. R. Peterson et al., “Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer,” Journal of Clinical Oncology, vol. 30, no. 3, pp. 300–307, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Oldenburg, S. M. Kraggerud, M. Brydoy, M. Cvancarova, R. A. Lothe, and S. D. Fossa, “Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study,” Journal of Translational Medicine, vol. 5, no. 1, p. 70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. M. E. Dolan, O. El Charif, H. E. Wheeler et al., “Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer,” Clinical Cancer Research, vol. 23, no. 19, pp. 5757–5768, 2017. View at Google Scholar
  74. A. Sawant, A. Kothandapani, A. Zhitkovich, R. W. Sobol, and S. M. Patrick, “Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links,” DNA Repair, vol. 35, pp. 126–136, 2015. View at Publisher · View at Google Scholar · View at Scopus
  75. J. C. Morales, P. Richard, A. Rommel et al., “Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair,” Nucleic Acids Research, vol. 42, no. 8, pp. 4996–5006, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. D. L. Hershman, C. Lacchetti, R. H. Dworkin et al., “Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline,” Journal of Clinical Oncology, vol. 32, no. 18, pp. 1941–1967, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. C. A. Bauer and T. J. Brozoski, “Cochlear structure and function after round window application of ototoxins,” Hearing Research, vol. 201, no. 1-2, pp. 121–131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Bokemeyer, C. C. Berger, J. T. Hartmann et al., “Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer,” British Journal of Cancer, vol. 77, no. 8, pp. 1355–1362, 1998. View at Publisher · View at Google Scholar
  79. R. D. Frisina, H. E. Wheeler, S. D. Fossa et al., “Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer,” Journal of Clinical Oncology, vol. 34, no. 23, pp. 2712–2720, 2016. View at Publisher · View at Google Scholar · View at Scopus
  80. L. P. Rybak, “Mechanisms of cisplatin ototoxicity and progress in otoprotection,” Current Opinion in Otolaryngology & Head and Neck Surgery, vol. 15, no. 5, pp. 364–369, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Riedemann, C. Lanvers, D. Deuster et al., “Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin,” Pharmacogenomics Journal, vol. 8, no. 1, pp. 23–28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Oldenburg, S. M. Kraggerud, M. Cvancarova, R. A. Lothe, and S. D. Fossa, “Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors,” Journal of Clinical Oncology, vol. 25, no. 6, pp. 708–714, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. C. J. Ross, H. Katzov-Eckert, M. P. Dube et al., “Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy,” Nature Genetics, vol. 41, no. 12, pp. 1345–1349, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. H. E. Wheeler, E. R. Gamazon, R. D. Frisina et al., “Variants in WFS1 and other Mendelian deafness genes are associated with cisplatin-associated ototoxicity,” Clinical Cancer Research, vol. 23, no. 13, pp. 3325–3333, 2016. View at Publisher · View at Google Scholar
  85. H. E. Wheeler, R. D. Frisina, E. R. Gamazon et al., “Genome-wide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal associated variant in wolfram syndrome 1 (WFS1) gene,” Journal of Clinical Oncology, vol. 34, no. 15, p. 10015, 2016. View at Publisher · View at Google Scholar
  86. K. Cryns, T. A. Sivakumaran, J. M. Van den Ouweland et al., “Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease,” Human Mutation, vol. 22, no. 4, pp. 275–287, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. H. Inoue, Y. Tanizawa, J. Wasson et al., “A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (wolfram syndrome),” Nature Genetics, vol. 20, no. 2, pp. 143–148, 1998. View at Publisher · View at Google Scholar · View at Scopus
  88. S. D. Fossa, R. de Wit, J. T. Roberts et al., “Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20),” Journal of Clinical Oncology, vol. 21, no. 6, pp. 1107–1118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. J. M. O’Sullivan, R. A. Huddart, A. R. Norman, J. Nicholls, D. P. Dearnaley, and A. Horwich, “Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours,” Annals of Oncology, vol. 14, no. 1, pp. 91–96, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. A. B. Simpson, J. Paul, J. Graham, and S. B. Kaye, “Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours,” British Journal of Cancer, vol. 78, no. 8, pp. 1061–1066, 1998. View at Publisher · View at Google Scholar
  91. S. Sleijfer, “Bleomycin-induced pneumonitis,” Chest, vol. 120, no. 2, pp. 617–624, 2001. View at Publisher · View at Google Scholar · View at Scopus
  92. H. S. Haugnes, N. Aass, S. D. Fossa et al., “Pulmonary function in long-term survivors of testicular cancer,” Journal of Clinical Oncology, vol. 27, no. 17, pp. 2779–2786, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. H. S. Haugnes, J. Oldenburg, and R. M. Bremnes, “Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors,” Urologic Oncology, vol. 33, no. 9, pp. 399–406, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. S. M. Donat and D. A. Levy, “Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?” Journal of Urology, vol. 160, no. 4, pp. 1347–1352, 1998. View at Publisher · View at Google Scholar · View at Scopus
  95. R. de Wit, S. Sleijfer, S. B. Kaye et al., “Bleomycin and scuba diving: where is the harm?” Lancet Oncology, vol. 8, no. 11, pp. 954-955, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. A. A. Ferrando, A. M. Pendas, E. Llano, G. Velasco, R. Lidereau, and C. López-Otı́n, “Gene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolase,” Journal of Biological Chemistry, vol. 272, no. 52, pp. 33298–33304, 1997. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Nuver, M. F. Lutke Holzik, M. van Zweeden et al., “Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients,” Pharmacogenetics and Genomics, vol. 15, no. 6, pp. 399–405, 2005. View at Publisher · View at Google Scholar
  98. A. E. Vickers, K. Rose, R. Fisher, M. Saulnier, P. Sahota, and P. Bentley, “Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology,” Toxicologic Pathology, vol. 32, no. 5, pp. 577–590, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. H. Tanaka, E. Ishikawa, S. Teshima, and E. Shimizu, “Histopathological study of human cisplatin nephropathy,” Toxicologic Pathology, vol. 14, no. 2, pp. 247–257, 1986. View at Publisher · View at Google Scholar
  100. S. D. Fossa, N. Aass, M. Winderen, O. P. Börmer, and D. R. Olsen, “Long-term renal function after treatment for malignant germ-cell tumours,” Annals of Oncology, vol. 13, no. 2, pp. 222–228, 2002. View at Publisher · View at Google Scholar · View at Scopus
  101. S. W. Hansen, S. Groth, G. Daugaard, N. Rossing, and M. Rørth, “Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer,” Journal of Clinical Oncology, vol. 6, no. 11, pp. 1728–1731, 1988. View at Publisher · View at Google Scholar
  102. J. M. Peacock, T. Ohira, W. Post, N. Sotoodehnia, W. Rosamond, and A. R. Folsom, “Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study,” American Heart Journal, vol. 160, no. 3, pp. 464–470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. B. C. Astor, S. I. Hallan, E. R. Miller III, E. Yeung, and J. Coresh, “Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population,” American Journal of Epidemiology, vol. 167, no. 10, pp. 1226–1234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. J. T. Hartmann, C. Kollmannsberger, L. Kanz, and C. Bokemeyer, “Platinum organ toxicity and possible prevention in patients with testicular cancer,” International Journal of Cancer, vol. 83, no. 6, pp. 866–869, 1999. View at Publisher · View at Google Scholar
  105. M. Sprauten, M. Brydoy, H. S. Haugnes et al., “Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors,” Journal of Clinical Oncology, vol. 32, no. 6, pp. 571–578, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. J. Eberhard, O. Stahl, M. Cwikiel et al., “Risk factors for post-treatment hypogonadism in testicular cancer patients,” European Journal of Endocrinology, vol. 158, no. 4, pp. 561–570, 2008. View at Publisher · View at Google Scholar
  107. C. Nord, T. Bjoro, D. Ellingsen et al., “Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer,” European Urology, vol. 44, no. 3, pp. 322–328, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Brydoy, S. D. Fossa, O. Dahl, and T. Bjøro, “Gonadal dysfunction and fertility problems in cancer survivors,” Acta Oncologica, vol. 46, no. 4, pp. 480–489, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. R. A. Huddart, A. Norman, C. Moynihan et al., “Fertility, gonadal and sexual function in survivors of testicular cancer,” British Journal of Cancer, vol. 93, no. 2, pp. 200–207, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Bandak, N. Jorgensen, A. Juul et al., “Testosterone deficiency in testicular cancer survivors - a systematic review and meta-analysis,” Andrology, vol. 4, no. 3, pp. 382–388, 2016. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Eberhard, O. Stahl, G. Cohn-Cedermark et al., “Sexual function in men treated for testicular cancer,” Journal of Sexual Medicine, vol. 6, no. 7, pp. 1979–1989, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Brydoy, S. D. Fossa, O. Klepp et al., “Paternity following treatment for testicular cancer,” Journal of the National Cancer Institute, vol. 97, no. 21, pp. 1580–1588, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. A. A. Dahl, R. Bremnes, O. Dahl, O. Klepp, E. Wist, and S. D. Fosså, “Is the sexual function compromised in long-term testicular cancer survivors?” European Urology, vol. 52, no. 5, pp. 1438–1447, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. J. Hintikka, L. Niskanen, H. Koivumaa-Honkanen et al., “Hypogonadism, decreased sexual desire, and long-term depression in middle-aged men,” Journal of Sexual Medicine, vol. 6, no. 7, pp. 2049–2057, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Bhasin, G. R. Cunningham, F. J. Hayes et al., “Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline,” Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 6, pp. 2536–2559, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. M. Ondrusova, D. Ondrus, L. Dusek, and B. Spanikova, “Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer,” Neoplasma, vol. 56, no. 6, pp. 473–479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. V. Rochira, A. Balestrieri, B. Madeo, L. Zirilli, A. R. Granata, and C. Carani, “Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology,” European Journal of Endocrinology, vol. 154, no. 2, pp. 175–185, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Abu Zaid, A. G. Menendez, O. E. Charif et al., “Adverse health outcomes in relationship to hypogonadism (HG) after platinum-based chemotherapy: a multicenter study of North American testicular cancer survivors (TCS),” Journal of Clinical Oncology, vol. 35, no. 18, 2017. View at Publisher · View at Google Scholar
  119. S. D. Fossa, T. Abyholm, and A. Aakvaag, “Spermatogenesis and hormonal status after orchiectomy for cancer and before supplementary treatment,” European Urology, vol. 10, no. 3, pp. 173–177, 1984. View at Publisher · View at Google Scholar
  120. K. P. Dieckmann, J. Linke, U. Pichlmeier, M. Kulejewski, and V. Loy, “Spermatogenesis in the contralateral testis of patients with testicular germ cell cancer: histological evaluation of testicular biopsies and a comparison with healthy males,” BJU International, vol. 99, no. 5, pp. 1079–1085, 2007. View at Publisher · View at Google Scholar · View at Scopus
  121. E. Huyghe, T. Matsuda, M. Daudin et al., “Fertility after testicular cancer treatments: results of a large multicenter study,” Cancer, vol. 100, no. 4, pp. 732–737, 2004. View at Publisher · View at Google Scholar · View at Scopus
  122. J. R. Spermon, L. A. Kiemeney, E. J. Meuleman, L. Ramos, A. M. M. Wetzels, and J. A. Witjes, “Fertility in men with testicular germ cell tumors,” Fertility and Sterility, vol. 79, pp. 1543–1549, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Brydoy, S. D. Fossa, O. Klepp et al., “Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy,” European Urology, vol. 58, no. 1, pp. 134–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. W. Gordon Jr., K. Siegmund, T. H. Stanisic et al., “A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group,” International Journal of Radiation Oncology Biology Physics, vol. 38, no. 1, pp. 83–94, 1997. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Brydoy, S. D. Fossa, O. Klepp et al., “Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer,” British Journal of Cancer, vol. 107, no. 11, pp. 1833–1839, 2012. View at Publisher · View at Google Scholar · View at Scopus
  126. K. A. Ostrowski and T. J. Walsh, “Infertility with testicular cancer,” Urologic Clinics of North America, vol. 42, no. 3, pp. 409–420, 2015. View at Publisher · View at Google Scholar · View at Scopus
  127. L. Gandini, P. Sgro, F. Lombardo et al., “Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients,” Human Reproduction, vol. 21, no. 11, pp. 2882–2889, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. H. Lampe, A. Horwich, A. Norman et al., “Fertility after chemotherapy for testicular germ cell cancers,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 239–245, 1997. View at Publisher · View at Google Scholar
  129. S. D. Beck, A. L. Bey, R. Bihrle et al., “Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection,” Journal of Urology, vol. 184, no. 5, pp. 2078–2080, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. V. S. Subramanian, C. T. Nguyen, A. J. Stephenson et al., “Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer,” Urologic Oncology, vol. 28, no. 5, pp. 504–509, 2010. View at Publisher · View at Google Scholar · View at Scopus
  131. A. Heidenreich, P. Albers, M. Hartmann et al., “Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group,” Journal of Urology, vol. 169, no. 5, pp. 1710–1714, 2003. View at Publisher · View at Google Scholar · View at Scopus
  132. K. D. Jacobsen, S. Ous, H. Waehre et al., “Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection,” British Journal of Cancer, vol. 80, no. 1-2, pp. 249–255, 1999. View at Publisher · View at Google Scholar · View at Scopus
  133. J. A. Pettus, B. S. Carver, T. Masterson, J. Stasi, and J. Sheinfeld, “Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer,” Urology, vol. 73, no. 2, pp. 328–331, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. C. L. Coogan, M. J. Hejase, G. R. Wahle et al., “Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer,” Journal of Urology, vol. 156, no. 5, pp. 1656–1658, 1996. View at Publisher · View at Google Scholar · View at Scopus
  135. A. Heidenreich, D. Pfister, R. Witthuhn, D. Thüer, and P. Albers, “Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection,” European Urology, vol. 55, no. 1, pp. 217–224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. A. W. Loren, P. B. Mangu, L. N. Beck et al., “Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update,” Journal of Clinical Oncology, vol. 31, no. 19, pp. 2500–2510, 2013. View at Publisher · View at Google Scholar · View at Scopus
  137. E. W. Winquist, G. S. Bauman, and J. Balogh, “Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review,” American Journal of Clinical Oncology, vol. 24, no. 6, pp. 603–606, 2001. View at Publisher · View at Google Scholar · View at Scopus
  138. A. M. Cook, A. S. Dzik-Jurasz, A. R. Padhani, A. Norman, and R. A. Huddart, “The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours,” British Journal of Cancer, vol. 85, no. 11, pp. 1624–1626, 2001. View at Publisher · View at Google Scholar · View at Scopus
  139. R. Kaila and R. L. Wolman, “Groin pain in athletes: a consequence of femoral head avascular necrosis after testicular cancer chemotherapy,” Clinical Journal of Sport Medicine, vol. 16, no. 2, pp. 175-176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  140. F. van den Berkmortel, R. de Wit, J. de Rooy, and P. DeMulder, “Osteonecrosis in patients with testicular tumours treated with chemotherapy,” Netherlands Journal of Medicine, vol. 62, no. 1, pp. 23–27, 2004. View at Google Scholar
  141. P. G. Harper, C. Trask, and R. L. Souhami, “Avascular necrosis of bone caused by combination chemotherapy without corticosteroids,” British Medical Journal, vol. 288, no. 6413, pp. 267-268, 1984. View at Publisher · View at Google Scholar
  142. M. B. de Ruiter, L. Reneman, W. Boogerd et al., “Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer,” Human Brain Mapping, vol. 32, no. 8, pp. 1206–1219, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. S. R. Kesler, F. C. Bennett, M. L. Mahaffey, and D. Spiegel, “Regional brain activation during verbal declarative memory in metastatic breast cancer,” Clinical Cancer Research, vol. 15, no. 21, pp. 6665–6673, 2009. View at Publisher · View at Google Scholar · View at Scopus
  144. D. H. Silverman, C. J. Dy, S. A. Castellon et al., “Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy,” Breast Cancer Research and Treatment, vol. 103, no. 3, pp. 303–311, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. B. Weiss, “Chemobrain: a translational challenge for neurotoxicology,” Neurotoxicology, vol. 29, no. 5, pp. 891–898, 2008. View at Publisher · View at Google Scholar · View at Scopus
  146. A. Amidi, L. M. Wu, M. Agerbaek et al., “Cognitive impairment and potential biological and psychological correlates of neuropsychological performance in recently orchiectomized testicular cancer patients,” Psycho-Oncology, vol. 24, no. 9, pp. 1174–1180, 2015. View at Publisher · View at Google Scholar · View at Scopus
  147. J. S. Wefel, D. J. Vidrine, T. L. Veramonti et al., “Cognitive impairment in men with testicular cancer prior to adjuvant therapy,” Cancer, vol. 117, no. 1, pp. 190–196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. S. B. Schagen, W. Boogerd, M. J. Muller et al., “Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer,” Acta Oncologica, vol. 47, no. 1, pp. 63–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  149. A. D. Pedersen, P. Rossen, M. Y. Mehlsen et al., “Long-term cognitive function following chemotherapy in patients with testicular cancer,” Journal of the International Neuropsychological Society, vol. 15, no. 2, pp. 296–301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. T. Skaali, S. D. Fossa, S. Andersson et al., “Self-reported cognitive problems in testicular cancer patients: relation to neuropsychological performance, fatigue, and psychological distress,” Journal of Psychosomatic Research, vol. 70, no. 5, pp. 403–410, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. J. Skoogh, G. Steineck, U. Stierner et al., “Testicular-cancer survivors experience compromised language following chemotherapy: findings in a Swedish population-based study 3-26 years after treatment,” Acta Oncologica, vol. 51, no. 2, pp. 185–197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  152. J. S. Wefel, D. J. Vidrine, S. K. Marani et al., “A prospective study of cognitive function in men with non-seminomatous germ cell tumors,” Psycho-Oncology, vol. 23, no. 6, pp. 626–633, 2014. View at Publisher · View at Google Scholar · View at Scopus
  153. A. A. Dahl, C. F. Haaland, A. Mykletun et al., “Study of anxiety disorder and depression in long-term survivors of testicular cancer,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2389–2395, 2005. View at Publisher · View at Google Scholar · View at Scopus
  154. S. Vehling, A. Mehnert, M. Hartmann, C. Oing, C. Bokemeyer, and K. Oechsle, “Anxiety and depression in long-term testicular germ cell tumor survivors,” General Hospital Psychiatry, vol. 38, pp. 21–25, 2016. View at Publisher · View at Google Scholar · View at Scopus
  155. E. H. Shinn, K. Basen-Engquist, B. Thornton, P. E. Spiess, and L. Pisters, “Health behaviors and depressive symptoms in testicular cancer survivors,” Urology, vol. 69, no. 4, pp. 748–753, 2007. View at Publisher · View at Google Scholar · View at Scopus
  156. A. B. Smith, P. Butow, I. Olver et al., “The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study,” Journal of Cancer Survivorship, vol. 10, no. 2, pp. 223–233, 2016. View at Publisher · View at Google Scholar · View at Scopus
  157. J. E. Bower, “Cancer-related fatigue–mechanisms, risk factors, and treatments,” Nature Reviews Clinical Oncology, vol. 11, no. 10, pp. 597–609, 2014. View at Publisher · View at Google Scholar · View at Scopus
  158. I. J. Orre, S. D. Fossa, R. Murison et al., “Chronic cancer-related fatigue in long-term survivors of testicular cancer,” Journal of Psychosomatic Research, vol. 64, no. 4, pp. 363–371, 2008. View at Publisher · View at Google Scholar · View at Scopus
  159. M. Sprauten, H. S. Haugnes, M. Brydoy et al., “Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors,” Annals of Oncology, vol. 26, no. 10, pp. 2133–2140, 2015. View at Publisher · View at Google Scholar · View at Scopus
  160. K. M. Mustian, C. M. Alfano, C. Heckler et al., “Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis,” JAMA Oncology, vol. 3, no. 7, pp. 961–968, 2017. View at Publisher · View at Google Scholar
  161. L. B. Travis, C. Beard, J. M. Allan et al., “Testicular cancer survivorship: research strategies and recommendations,” Journal of the National Cancer Institute, vol. 102, no. 15, pp. 1114–1130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  162. K. D. Miller, R. L. Siegel, C. C. Lin et al., “Cancer treatment and survivorship statistics, 2016,” CA: A Cancer Journal for Clinicians, vol. 66, no. 4, pp. 271–289, 2016. View at Publisher · View at Google Scholar · View at Scopus
  163. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, “Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Google Scholar
  164. L. Richiardi, G. Scelo, P. Boffetta et al., “Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries,” International Journal of Cancer, vol. 120, no. 3, pp. 623–631, 2007. View at Publisher · View at Google Scholar · View at Scopus
  165. K. Hemminki, H. Liu, and J. Sundquist, “Second cancers after testicular cancer diagnosed after 1980 in Sweden,” Annals of Oncology, vol. 21, no. 7, pp. 1546–1551, 2010. View at Publisher · View at Google Scholar · View at Scopus
  166. I. M. Ventry and B. E. Weinstein, “The hearing handicap inventory for the elderly: a new tool,” Ear and Hearing, vol. 3, no. 3, pp. 128–134, 1982. View at Publisher · View at Google Scholar
  167. European Organisation for Research and Treatment of Cancer, First EORTC Cancer Survivorship Summit, vol. 12, European Journal of Cancer Supplements, Brussels, Belgium, June 2014.
  168. J. Oldenburg, S. D. Fossa, and A. A. Dahl, “Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors,” Quality of Life Research, vol. 15, no. 5, pp. 791–800, 2006. View at Publisher · View at Google Scholar · View at Scopus
  169. L. B. Travis, “Therapy-associated solid tumors,” Acta Oncologica, vol. 41, no. 4, pp. 323–333, 2002. View at Publisher · View at Google Scholar · View at Scopus